Takeda Turnaround In Full Flow As New Products Deliver
This article was originally published in PharmAsia News
Takeda has closed out its "turnaround year" on target, meeting guidance for fiscal 2015. The company has been undergoing a reorganization to pull it through intense generic competition and CEO Christophe Weber took the year-end opportunity to outline how the strategy was playing out for the Japanese pharma, and also to stress its continued commitment to the ‘up and down’ emerging markets.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.